

K050864

1/2

JUN 17 2005

## 510(k) Summary

### ArthroCare Corporation Parallax<sup>®</sup> Acrylic Resin Kit with TRACERS<sup>®</sup> Ta Bone Cement Opacifier

#### General Information

**Submitter Name/Address:** ArthroCare Corporation  
680 Vaqueros Avenue  
Sunnyvale, CA 94085-3523

**Establishment Registration Number:** 2951580

**Contact Person:** Valerie Defiesta-Ng  
Director, Regulatory Affairs

**Date Prepared:** April 4, 2005

#### Device Description

**Trade Name:** Parallax<sup>®</sup> Acrylic Resin with TRACERS<sup>®</sup> Ta

**Classification Name:** Bone Cement (21 CFR 888.3027)

**Device Classification:** Class II  
Panel: Orthopedic Devices

#### Predicate Devices

Parallax<sup>®</sup> Acrylic Resin with TRACERS<sup>®</sup> K042947

#### Product Description

Parallax Acrylic Resin with TRACERS Ta is an opacified polymethylmethacrylate (PMMA) bone cement.

#### Intended Uses

Parallax Acrylic Resin with TRACERS Ta is indicated for the fixation of pathological fractures of the vertebral body using vertebroplasty or kyphoplasty procedures. Painful vertebral compression fractures may result from osteoporosis, benign lesions (hemangioma), and malignant lesions (metastatic cancers, myeloma).

**Substantial Equivalence**

This Special 510(k) proposes a material modification for the Parallax Acrylic Resin with TRACERS, which was previously cleared in K042947 on December 27, 2004. The indications for use, technology, principle of operation, packaging and sterilization parameters of the Parallax Acrylic Resin with TRACERS remain the same as in the predicate cleared 510(k).

**Summary of Safety and Effectiveness**

The modified Parallax Acrylic Resin with TRACERS, as described in this Special 510(k), is substantially equivalent to the predicate device. The proposed modification in material is not a substantial change or modification, and does not significantly affect the safety or efficacy of the device.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

JUN 17 2005

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Ms. Valerie Defiesta-Ng  
Director, Regulatory Affairs  
ArthroCare Corporation  
680 Vaqueros Avenue  
Sunnyvale, California 94085-3523

Re: K050864

Trade/Device Name: Parallax® Acrylic Resin with TRACERS® TA  
Regulation Number: 21 CFR 888.3027  
Regulation Name: Polymethylmethacrylate (PMMA) bone cement  
Regulatory Class: II  
Product Code: NDN,LOD  
Dated: April 4, 2005  
Received: April 5, 2005

Dear Ms. Defiesta-Ng:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120 . Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Miriam C. Provost", is written over the typed name.

Miriam C. Provost, Ph.D.

Acting Director

Division of General, Restorative  
and Neurological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K050864

Device Name: Parallax<sup>®</sup> Acrylic Resin with TRACERS<sup>®</sup> Ta

### Indications for Use:

Parallax<sup>®</sup> Acrylic Resin with TRACERS<sup>®</sup> Ta is indicated for the fixation of pathological fractures of the vertebral body using vertebroplasty or kyphoplasty procedures. Painful vertebral compression fractures may result from osteoporosis, benign lesions (hemangioma), and malignant lesions (metastatic cancer, myeloma).

Prescription Use  
(Part 21 CFR 801 Subpart D)

X


AND/OR

Over-the-Counter Use  
(21 CFR 801 Subpart C)

---

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
(Division Sign-Off)  
**Division of General, Restorative,  
and Neurological Devices**

510(k) Number K050864